The Fukuoka Kidney disease Registry (FKR) Study

design and methods

Fukuoka Kidney disease Registry (FKR) Study Collaboration Group

Research output: Contribution to journalArticle

Abstract

Background: Chronic kidney disease (CKD) is an established independent risk factor for progression to end-stage renal disease (ESRD) and incidence of cardiovascular disease (CVD). The onset and progression of CKD are associated with both genetic predisposition and various lifestyle-related factors, but little is known about the influence of genetic-environmental interactions on the incidence of ESRD or CVD in patients with CKD. Methods: The Fukuoka Kidney disease Registry (FKR) Study is designed as one of the largest prospective, multicenter, observational cohort studies in non-dialysis dependent CKD patients. The FKR Study aims to enroll approximately 5000 individuals at multiple clinical centers and follow them for up to at least 5 years. At baseline, subjects enrolled in the FKR Study will fill out extensive lifestyle-related questionnaires. Further, their health status and treatments will be monitored annually through a research network of nephrology centers. Blood and urine samples, including DNA/RNA, will be collected at the time of enrolment and every 5-years follow-up. Conclusions: The FKR Study will provide many insights into the onset and progression of CKD, which will suggest hypothesis-driven interventional clinical trials aimed at reducing the burden of CKD. The features of the FKR Study may also facilitate innovative research to identify and validate novel risk factors, including genetic susceptibility and biomarkers, using biomaterials by high-throughput omics technologies.

Original languageEnglish
Pages (from-to)465-473
Number of pages9
JournalClinical and Experimental Nephrology
Volume21
Issue number3
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Kidney Diseases
Chronic Renal Insufficiency
Registries
Genetic Predisposition to Disease
Chronic Kidney Failure
Life Style
Cardiovascular Diseases
Nephrology
Incidence
Biocompatible Materials
Research
Health Status
Observational Studies
Cohort Studies
Biomarkers
Clinical Trials
Urine
RNA
Technology
DNA

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

The Fukuoka Kidney disease Registry (FKR) Study : design and methods. / Fukuoka Kidney disease Registry (FKR) Study Collaboration Group.

In: Clinical and Experimental Nephrology, Vol. 21, No. 3, 01.06.2017, p. 465-473.

Research output: Contribution to journalArticle

Fukuoka Kidney disease Registry (FKR) Study Collaboration Group 2017, 'The Fukuoka Kidney disease Registry (FKR) Study: design and methods', Clinical and Experimental Nephrology, vol. 21, no. 3, pp. 465-473. https://doi.org/10.1007/s10157-016-1294-4
Fukuoka Kidney disease Registry (FKR) Study Collaboration Group. / The Fukuoka Kidney disease Registry (FKR) Study : design and methods. In: Clinical and Experimental Nephrology. 2017 ; Vol. 21, No. 3. pp. 465-473.
@article{5beaa46eb1114d49ae3dd4d56df62665,
title = "The Fukuoka Kidney disease Registry (FKR) Study: design and methods",
abstract = "Background: Chronic kidney disease (CKD) is an established independent risk factor for progression to end-stage renal disease (ESRD) and incidence of cardiovascular disease (CVD). The onset and progression of CKD are associated with both genetic predisposition and various lifestyle-related factors, but little is known about the influence of genetic-environmental interactions on the incidence of ESRD or CVD in patients with CKD. Methods: The Fukuoka Kidney disease Registry (FKR) Study is designed as one of the largest prospective, multicenter, observational cohort studies in non-dialysis dependent CKD patients. The FKR Study aims to enroll approximately 5000 individuals at multiple clinical centers and follow them for up to at least 5 years. At baseline, subjects enrolled in the FKR Study will fill out extensive lifestyle-related questionnaires. Further, their health status and treatments will be monitored annually through a research network of nephrology centers. Blood and urine samples, including DNA/RNA, will be collected at the time of enrolment and every 5-years follow-up. Conclusions: The FKR Study will provide many insights into the onset and progression of CKD, which will suggest hypothesis-driven interventional clinical trials aimed at reducing the burden of CKD. The features of the FKR Study may also facilitate innovative research to identify and validate novel risk factors, including genetic susceptibility and biomarkers, using biomaterials by high-throughput omics technologies.",
author = "{Fukuoka Kidney disease Registry (FKR) Study Collaboration Group} and Shigeru Tanaka and Shigeru Tanaka and Toshiharu Ninomiya and Hisako Yoshida and Kiichiro Fujisaki and Kosuke Masutani and Masanori Tokumoto and Koji Mitsuiki and Hideki Hirakata and Satoru Fujimi and Yutaka Kiyohara and Takanari Kitazono and Takanari Kitazono",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s10157-016-1294-4",
language = "English",
volume = "21",
pages = "465--473",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - The Fukuoka Kidney disease Registry (FKR) Study

T2 - design and methods

AU - Fukuoka Kidney disease Registry (FKR) Study Collaboration Group

AU - Tanaka, Shigeru

AU - Tanaka, Shigeru

AU - Ninomiya, Toshiharu

AU - Yoshida, Hisako

AU - Fujisaki, Kiichiro

AU - Masutani, Kosuke

AU - Tokumoto, Masanori

AU - Mitsuiki, Koji

AU - Hirakata, Hideki

AU - Fujimi, Satoru

AU - Kiyohara, Yutaka

AU - Kitazono, Takanari

AU - Kitazono, Takanari

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: Chronic kidney disease (CKD) is an established independent risk factor for progression to end-stage renal disease (ESRD) and incidence of cardiovascular disease (CVD). The onset and progression of CKD are associated with both genetic predisposition and various lifestyle-related factors, but little is known about the influence of genetic-environmental interactions on the incidence of ESRD or CVD in patients with CKD. Methods: The Fukuoka Kidney disease Registry (FKR) Study is designed as one of the largest prospective, multicenter, observational cohort studies in non-dialysis dependent CKD patients. The FKR Study aims to enroll approximately 5000 individuals at multiple clinical centers and follow them for up to at least 5 years. At baseline, subjects enrolled in the FKR Study will fill out extensive lifestyle-related questionnaires. Further, their health status and treatments will be monitored annually through a research network of nephrology centers. Blood and urine samples, including DNA/RNA, will be collected at the time of enrolment and every 5-years follow-up. Conclusions: The FKR Study will provide many insights into the onset and progression of CKD, which will suggest hypothesis-driven interventional clinical trials aimed at reducing the burden of CKD. The features of the FKR Study may also facilitate innovative research to identify and validate novel risk factors, including genetic susceptibility and biomarkers, using biomaterials by high-throughput omics technologies.

AB - Background: Chronic kidney disease (CKD) is an established independent risk factor for progression to end-stage renal disease (ESRD) and incidence of cardiovascular disease (CVD). The onset and progression of CKD are associated with both genetic predisposition and various lifestyle-related factors, but little is known about the influence of genetic-environmental interactions on the incidence of ESRD or CVD in patients with CKD. Methods: The Fukuoka Kidney disease Registry (FKR) Study is designed as one of the largest prospective, multicenter, observational cohort studies in non-dialysis dependent CKD patients. The FKR Study aims to enroll approximately 5000 individuals at multiple clinical centers and follow them for up to at least 5 years. At baseline, subjects enrolled in the FKR Study will fill out extensive lifestyle-related questionnaires. Further, their health status and treatments will be monitored annually through a research network of nephrology centers. Blood and urine samples, including DNA/RNA, will be collected at the time of enrolment and every 5-years follow-up. Conclusions: The FKR Study will provide many insights into the onset and progression of CKD, which will suggest hypothesis-driven interventional clinical trials aimed at reducing the burden of CKD. The features of the FKR Study may also facilitate innovative research to identify and validate novel risk factors, including genetic susceptibility and biomarkers, using biomaterials by high-throughput omics technologies.

UR - http://www.scopus.com/inward/record.url?scp=84976287048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976287048&partnerID=8YFLogxK

U2 - 10.1007/s10157-016-1294-4

DO - 10.1007/s10157-016-1294-4

M3 - Article

VL - 21

SP - 465

EP - 473

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 3

ER -